Related Posts

• MIT Teams With Italian Energy Giant, Elixir Postpones Its IPO, Biogen Idec Will Buy or Be Bought, & More
• Sepracor Licenses Epilepsy Drug
• Xanthus Sold for $52M
• Concert Strikes a Chord With Investors, Abiomed Scores a Win with Medicare, Epix Snags $7.5M from GSK, & More Life Sciences News
• Cornerstone Buys Critical Therapeutics

deals, Drugs, FDA

Hologic Grabs $82M for Drug

Rebecca Zacks 1/22/08 12:09 pm

Medical technology megafirm Hologic (NASDAQ: HOLX), which develops diagnostics, imaging tools, and other devices focused on women’s healthcare, announced today that it will sell the rights to its drug Gestiva for $82 million in cash to St. Louis, MO-based KV Pharmaceutical. Bedford, MA-based Hologic acquired the rights to Gestiva, a treatment for the prevention of preterm birth, in its $6.2 billion merger with Cytyc back in the fall. Hologic won’t collect $82 million of the purchase price for Gestiva until the drug earns FDA approval.

Permalink | Share |

Why is this story so short? Because it's a news brief from our News Xpress section, which brings you quick takes on the latest Boston-area biz/tech news as it unfolds throughout the day.

Where do I find more in-depth news and analysis about the business of technology in the Boston area? We've got plenty of that right on our home page and in our archives.

Who the heck are the Xconomists mentioned on your homepage? They're an elite group of movers and shakers in the local tech scene who've generously agreed to share their insights and opinions with Xconomy's readers. Here's a complete list of them; to read their posts, have a look here and here.

Come to think of it, what does "Xconomy" mean in the first place? Xconomy is a word we made up to evoke the exponential economy—the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth. (Not everybody likes the name, by the way. We're okay with that.) We're a small group of professional journalists dedicated to bringing you the most important news about New England's role in the exponential economy. More on our mission and team here.